Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

In VitroandIn VivoActivity of Miltefosine Against Penicillin-Sensitive and -ResistantStreptococcus pneumoniaeStrains

(2014) L. Huelves et al.   JOURNAL OF CHEMOTHERAPY

Kinetoplastida: new therapeutic strategies

(2013) S.L. Croft   Parasite

Leishmaniasis in the United States: Treatment in 2012

(2012) Henry W. Murray   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Characterization and identification of suspected counterfeit miltefosine capsules

(2012) Thomas P. C. Dorlo et al.   ANALYST

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis

(2012) Thomas P. C. Dorlo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum

(2012) Shahram Khademvatan et al.   Brazilian Journal of Infectious Diseases

Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children

(2012) Luisa Consuelo Rubiano et al.   JOURNAL OF INFECTIOUS DISEASES

Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms

(2012) Humberto Gonçalves Bertão et al.   PARASITOLOGY RESEARCH

Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis

(2012) H. E. Cummings et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal

(2012) Thomas P. C. Dorlo et al.   PLoS Neglected Tropical Diseases

Multiple Mutations in Heterogeneous Miltefosine-Resistant Leishmania major Population as Determined by Whole Genome Sequencing

(2012) Adriano C. Coelho et al.   PLoS Neglected Tropical Diseases

Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia

(2011) Michael O. Harhay et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

(2011) Anette Chrusciak-Talhari et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh

(2011) Mahmudur Rahman et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

In a trial of the use of miltefosine to treat HIV‐related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality

(2011) E Sinkala et al.   ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

(2011) V. Ramesh et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes

(2011) Fernanda de Aquino Marinho et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Miltefosine Induces Apoptosis-Like Cell Death in Yeast via Cox9p in Cytochrome c Oxidase

(2011) X. Zuo et al.   MOLECULAR PHARMACOLOGY

Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters

(2011) Zubeyde Akın Polat et al.   PARASITOLOGY RESEARCH

Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial

(2011) Tansy Edwards et al.   Trials

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

(2011) Raymond Omollo et al.   Trials

Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania

(2011) W Moreira et al.   Cell Death & Disease

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine

(2011) Thomas P. C. Dorlo et al.   PLoS Neglected Tropical Diseases

Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis

(2010) Iván Vélez et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Designing and Reporting Clinical Trials on Treatments for Cutaneous Leishmaniasis

(2010) Urbà González et al.   CLINICAL INFECTIOUS DISEASES

Miltefosine, a promising novel agent for schistosomiasis mansoni

(2010) Maha M. Eissa et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

Oral miltefosine in post-kala-azar dermal leishmaniasis - experience in three cases

(2010) Sujay Khandpur et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent

(2010) K. Seifert et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography–tandem mass spectrometric detection

(2010) Hongliang Jiang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Combination therapy for visceral leishmaniasis

(2010) Johan van Griensven et al.   LANCET INFECTIOUS DISEASES

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PI3K/Akt Cell Survival Pathway to Induce Cell Death of HIV-1 Infected Macrophages with Alkylphospholipid Compounds

(2010) Amanda Lucas et al.   PLoS One

Disruption of the Lipid-Transporting LdMT-LdRos3 Complex in Leishmania donovani Affects Membrane Lipid Asymmetry but Not Host Cell Invasion

(2010) Adrien Weingärtner et al.   PLoS One

Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - the challenges for diagnosis and treatment

(2010) Shyam Sundar et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

(2010) Ahmed M. Musa et al.   PLoS Neglected Tropical Diseases

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

(2010) Asrat Hailu et al.   PLoS Neglected Tropical Diseases

Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent

(2010) Filip Meheus et al.   PLoS Neglected Tropical Diseases

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial

(2010) Paulo R. Machado et al.   PLoS Neglected Tropical Diseases

Erratum

(2009)   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Miltefosine Efficiently Eliminates Leishmania major Amastigotes from Infected Murine Dendritic Cells without Altering Their Immune Functions

(2009) K. Griewank et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug

(2009) M. P. Sanchez-Canete et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences

(2009) M. Vermeersch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host Cells

(2009) R. Inocencio da Luz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial

(2009) K. Hartmann et al.   BRITISH JOURNAL OF DERMATOLOGY

Miltefosine Treatment ofLeishmania majorInfection: An Observational Study Involving Dutch Military Personnel Returning from Northern Afghanistan

(2009) P. P. A. M. van Thiel et al.   CLINICAL INFECTIOUS DISEASES

Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent

(2009) J. Walochnik et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Miltefosine Promotes IFN- -Dominated Anti-Leishmanial Immune Response

(2009) P. Wadhone et al.   JOURNAL OF IMMUNOLOGY

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells

(2009) D. Liu et al.   JOURNAL OF IMMUNOLOGY

Administration of Miltefosine and Meglumine Antimoniate in Healthy Dogs: Clinicopathological Evaluation of the Impact on the Kidneys

(2009) Paolo Bianciardi et al.   TOXICOLOGIC PATHOLOGY

Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases

(2009) T. A. Patel et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India

(2009) Piero Olliaro et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum

(2009) M. Shahiduzzaman et al.   VETERINARY PARASITOLOGY

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

(2008) T. P. C. Dorlo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement

(2008) E. Castanys-Munoz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral Miltefosine

(2008) Shyam Sundar et al.   CLINICAL INFECTIOUS DISEASES

Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects

(2008) Wim van Blitterswijk et al.   CURRENT PHARMACEUTICAL DESIGN

Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells

(2008) María P. Carrasco et al.   FEBS Journal

Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine)

(2008) Krittalak Chakrabandhu et al.   FEBS LETTERS

Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography–tandem mass spectrometry using a deuterated internal standard

(2008) L LINDNER et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometry

(2008) Thomas P.C. Dorlo et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy

(2008) Pauline Chugh et al.   Retrovirology

Pentamidine Dosage: A Base/Salt Confusion

(2008) Thomas P. C. Dorlo et al.   PLoS Neglected Tropical Diseases